v3.26.1
Condensed Consolidated Statements of Stockholders’ Equity - USD ($)
$ in Thousands
Total
Common Stock
Additional Paid-In Capital
Accumulated Deficit
Accumulated Other Comprehensive Loss
Balances, beginning of period (in shares) at Dec. 31, 2024   129,012,000      
Balances, beginning of period at Dec. 31, 2024 $ 107,287 $ 13 $ 307,756 $ (200,482) $ 0
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Issuance of shares for cash (in shares)   22,198,000      
Issuance of shares for cash 281,642 $ 2 281,640    
Issuance of shares related to exercise of warrants (in shares)   1,556,000      
Issuance of shares related to exercise of warrants $ 21,866 $ 1 21,865    
Stock-based compensation (in shares) 0 5,145,000      
Stock-based compensation $ 4,669   4,669    
Stock-based compensation for services 18   18    
Net loss (19,500)     (19,500)  
Balances, end of period (in shares) at Jun. 30, 2025   157,911,000      
Balances, end of period at Jun. 30, 2025 395,982 $ 16 615,948 (219,982) 0
Balances, beginning of period (in shares) at Mar. 31, 2025   137,322,000      
Balances, beginning of period at Mar. 31, 2025 220,827 $ 14 404,313 (183,500) 0
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Issuance of shares for cash (in shares)   14,035,000      
Issuance of shares for cash 188,006 $ 1 188,005    
Issuance of shares related to exercise of warrants (in shares)   1,550,000      
Issuance of shares related to exercise of warrants $ 21,854 $ 1 21,853    
Stock-based compensation (in shares) 0 5,004,000      
Stock-based compensation $ 1,777   1,777    
Net loss (36,482)     (36,482)  
Balances, end of period (in shares) at Jun. 30, 2025   157,911,000      
Balances, end of period at Jun. 30, 2025 395,982 $ 16 615,948 (219,982) 0
Balances, beginning of period (in shares) at Dec. 31, 2025   224,165,000      
Balances, beginning of period at Dec. 31, 2025 $ 1,598,265 $ 22 1,816,494 (219,156) 905
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Issuance of shares related to stock option exercises (in Shares) 1,206,000 1,206,000      
Issuance of shares related to stock option exercises $ 4,300 $ 1 4,299    
Shares released from escrow relating to settled litigation (in shares)   100,000      
Equity consideration for acquisitions (in shares)   447,000      
Equity consideration for acquisitions $ 7,038   7,038    
Stock-based compensation (in shares) 428,000 428,000      
Stock-based compensation $ 3,005   3,005    
Net loss (15,803)     (15,803)  
Unrealized losses on available-for-sale debt securities (4,767)       (4,767)
Balances, end of period (in shares) at Jun. 30, 2026   226,346,000      
Balances, end of period at Jun. 30, 2026 1,592,038 $ 23 1,830,836 (234,959) (3,862)
Balances, beginning of period (in shares) at Mar. 31, 2026   225,494,000      
Balances, beginning of period at Mar. 31, 2026 1,597,184 $ 23 1,823,284 (223,206) (2,917)
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Issuance of shares related to stock option exercises (in Shares)   350,000      
Issuance of shares related to stock option exercises 793   793    
Equity consideration for acquisitions (in shares)   447,000      
Equity consideration for acquisitions $ 5,000   5,000    
Stock-based compensation (in shares) 55,000 55,000      
Stock-based compensation $ 1,759   1,759    
Net loss (11,753)     (11,753)  
Unrealized losses on available-for-sale debt securities (945)       (945)
Balances, end of period (in shares) at Jun. 30, 2026   226,346,000      
Balances, end of period at Jun. 30, 2026 $ 1,592,038 $ 23 $ 1,830,836 $ (234,959) $ (3,862)